Literature DB >> 10541086

Spectrum of imaging findings of the liver in end-stage cirrhosis: Part II, focal abnormalities.

G D Dodd1, R L Baron, J H Oliver, M P Federle.   

Abstract

Cirrhosis, through the process of necrosis, fibrosis, regeneration, and malignant transformation, creates multiple focal benign and malignant hepatic masses. The detection and appearance of these masses varies with the severity of the cirrhotic process and the imaging technique used. Although some overlap exists in the imaging appearance of the benign and malignant masses, in most instances recognition of a few characteristic features will yield the correct diagnosis.

Entities:  

Mesh:

Year:  1999        PMID: 10541086     DOI: 10.2214/ajr.173.5.10541086

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  14 in total

1.  Potentially misleading CT findings in fatty liver cirrhosis.

Authors:  H Staedele; W Wiesner; M Heim; G Bongartz
Journal:  Eur Radiol       Date:  2001-09-26       Impact factor: 5.315

2.  Diagnosis of cirrhosis by spiral computed tomography: a case-control study with feature analysis and assessment of interobserver agreement.

Authors:  Alexander Keedy; Antonio C Westphalen; Aliya Qayyum; Rizwan Aslam; Alexander V Rybkin; Mei-Hsiu Chen; Fergus V Coakley
Journal:  J Comput Assist Tomogr       Date:  2008 Mar-Apr       Impact factor: 1.826

3.  Impaired visibility of the hepatic veins on the multi-detector computed tomography in patients with cirrhosis.

Authors:  Nilgun Isiksalan Ozbulbul; Mehmet Yurdakul; Muharrem Tola
Journal:  Eurasian J Med       Date:  2014-10

4.  Assessment of liver volume variation to evaluate liver function.

Authors:  Cong Tong; Xinsen Xu; Chang Liu; Tianzheng Zhang; Kai Qu
Journal:  Front Med       Date:  2012-09-28       Impact factor: 4.592

5.  Differentiating malignant from benign hyperintense nodules on unenhanced T1-weighted images in patients with chronic liver disease: using gadoxetic acid-enhanced and diffusion-weighted MR imaging.

Authors:  Ji Yoon Moon; Seong Hyun Kim; Seo-Youn Choi; Jeong Ah Hwang; Ji Eun Lee; Jisun Lee
Journal:  Jpn J Radiol       Date:  2018-06-06       Impact factor: 2.374

6.  Hepatic cavernous hemangiomas: long-term (> 5 years) follow-up changes on contrast-enhanced dynamic computed tomography or magnetic resonance imaging and determinant factors of the size change.

Authors:  Jiae Choi; Jeong-Sik Yu; Eun-Suk Cho; Joo Hee Kim; Jae-Joon Chung
Journal:  Radiol Med       Date:  2018-01-22       Impact factor: 3.469

Review 7.  Liver haemangioma: common and uncommon findings and how to improve the differential diagnosis.

Authors:  Filipe Caseiro-Alves; Jorge Brito; Antonio Eiras Araujo; Pedro Belo-Soares; Henrique Rodrigues; Augusta Cipriano; Daniel Sousa; Didier Mathieu
Journal:  Eur Radiol       Date:  2007-01-27       Impact factor: 5.315

Review 8.  Evidence Supporting LI-RADS Major Features for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review.

Authors:  An Tang; Mustafa R Bashir; Michael T Corwin; Irene Cruite; Christoph F Dietrich; Richard K G Do; Eric C Ehman; Kathryn J Fowler; Hero K Hussain; Reena C Jha; Adib R Karam; Adrija Mamidipalli; Robert M Marks; Donald G Mitchell; Tara A Morgan; Michael A Ohliger; Amol Shah; Kim-Nhien Vu; Claude B Sirlin
Journal:  Radiology       Date:  2017-11-21       Impact factor: 11.105

9.  Macro-regenerative nodules in biliary atresia: CT/MRI findings and their pathological relations.

Authors:  Jiun-Lung Liang; Yu-Fan Cheng; Allan-M Concejero; Tung-Liang Huang; Tai-Yi Chen; Leo-Leung-Chit Tsang; Hsin-You Ou
Journal:  World J Gastroenterol       Date:  2008-07-28       Impact factor: 5.742

10.  Imaging and Imaging-Guided Interventions in the Diagnosis and Management of Hepatocellular Carcinoma (HCC)-Review of Evidence.

Authors:  Hossein Ghanaati; Seyed Moayed Alavian; Ali Jafarian; Nasser Ebrahimi Daryani; Mohsen Nassiri-Toosi; Amir Hossein Jalali; Madjid Shakiba
Journal:  Iran J Radiol       Date:  2012-11-20       Impact factor: 0.212

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.